Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Compugen Ltd. (NASDAQ:CGEN) by 15.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,500 shares of the biotechnology company’s stock after acquiring an additional 43,165 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.36% of Compugen worth $486,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CGEN. Oppenheimer & Co. Inc. raised its stake in Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 8,350 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Compugen in the fourth quarter valued at $103,000. Finally, Atom Investors LP increased its stake in Compugen by 27.5% in the third quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 32,701 shares during the period. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Oppenheimer assumed coverage on shares of Compugen in a report on Monday, January 13th. They issued an “outperform” rating and a $4.00 target price on the stock. StockNews.com downgraded shares of Compugen from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Compugen Trading Down 1.9 %

CGEN stock opened at $1.57 on Friday. The company has a market cap of $140.10 million, a P/E ratio of 78.50 and a beta of 2.98. Compugen Ltd. has a 52 week low of $1.35 and a 52 week high of $2.67. The company’s 50-day moving average price is $2.05 and its 200 day moving average price is $1.81.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14). Compugen had a net margin of 2.67% and a return on equity of 2.62%. The business had revenue of $1.47 million during the quarter, compared to analysts’ expectations of $17.47 million. On average, equities research analysts expect that Compugen Ltd. will post -0.03 earnings per share for the current year.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.